Relevant bibliographies by topics / In-vivo testing

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'In-vivo testing'

Author: Grafiati
Published: 9 March 2023
Last updated: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'In-vivo testing.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "In-vivo testing"

1

Bautista, Levylee G., Dawn Grace E. Santos, Ghafoor A. Haque, Jr. I, Aishwarya V. Veluchamy, Jesusa E. Santos, and Rodolfo T. Rafael. "In Vivo Genotoxicity Testing of Sesbania grandiflora (Katuray) Flower Methanol Extract." International Journal of Pharma Medicine and Biological Sciences 11, no. 1 (January 2022): 14–19. http://dx.doi.org/10.18178/ijpmbs.11.1.14-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cook, Paul R. "In vivo testing and immunotherapy." Current Opinion in Otolaryngology & Head and Neck Surgery 2 (April 1994): 118–27. http://dx.doi.org/10.1097/00020840-199404000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Al-hadede, Lamees Thamer, Taghreed H. AL-Sadoon, Basma A. Jasim, and Huda Khmees Akaar. "In Vivo Testing of Coated Nanoparticles as Medication Delivery and Liver Integrity Monitoring in Mice's." NeuroQuantology 20, no. 3 (March 31, 2022): 318–24. http://dx.doi.org/10.14704/nq.2022.20.3.nq22282.

Full text
Abstract:
The study's goal is to assay the effect of using therapeutic nanoparticles on the liver. The study involves the estimation of aminotransferase ALT, AST and alkaline phosphate ALP levels in patients before and after using nanoparticles. Gold nanoparticles (Gnps) were created using a chemical method, then coated with polyethylene glycol (Peg), followed by Ultra violet spectrophotometry, transmission electron microscopy (TEM), and surface charge studies to determine their sizes, then were investigate the effect of using therapeutic nanoparticles on the liver. The results show that before coating with Peg, the size of Gnps was 22.65 and 23.82 nm, while after coating with Peg, the size of Gnps was 76.50 and 80.15 nm. The maximum absorption was at 515.5 nm and became 530.5 nm when using UV, and it was -29.65 and became -9.4 when using zeta potential, experiments are ongoing for (60) days. The result revealed that the liver enzymes (AST and ALT) has a significant effect when injecting Gnps. While the effect was less on both liver enzymes (AST and ALT) when injecting Gnps + Peg.
APA, Harvard, Vancouver, ISO, and other styles
4

Ownby, Dennis R. "Allergy Testing: In Vivo Versus In Vitro." Pediatric Clinics of North America 35, no. 5 (October 1988): 995–1009. http://dx.doi.org/10.1016/s0031-3955(16)36544-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maurer, Th. "Phototoxicity testing—in vivo and in vitro." Food and Chemical Toxicology 25, no. 5 (May 1987): 407–14. http://dx.doi.org/10.1016/0278-6915(87)90177-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bolotova, К. S., O. V. Buyuklinskaya, А. S. Chistyakova, О. V. Travina, and D. G. Chukhchin. "PRODUCTION AND IN VIVO TOXICITY TESTING OF MICROCRYSTALLINE CELLULOSE DERIVED FROM BACTERIAL CELLULOSE." Human Ecology, no. 2 (February 13, 2018): 21–25. http://dx.doi.org/10.33396/1728-0869-2018-2-21-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Levorová, J., J. Dušková, M. Drahoš, R. Vrbová, J. Kubásek, D. Vojtěch, M. Bartoš, L. Dugová, D. Ulmann, and R. Foltán. "Biodegradability of Metal Alloys: in vivo Testing." Česká stomatologie/Praktické zubní lékařství 117, no. 4 (December 1, 2017): 79–84. http://dx.doi.org/10.51479/cspzl.2017.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Levorová, J., J. Dušková, M. Drahoš, R. Vrbová, J. Kubásek, D. Vojtěch, M. Bartoš, L. Dugová, D. Ulmann, and R. Foltán. "Biodegradability of Metal Alloys: in vivo Testing." Česká stomatologie/Praktické zubní lékařství 117, no. 4 (December 1, 2017): 79–84. http://dx.doi.org/10.51479/cspzl.2017.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Szycher, Michael, Andrew M. Reed, and Arthur A. Siciliano. "In vivo Testing of a Biostable Polyurethane." Journal of Biomaterials Applications 6, no. 2 (October 1991): 110–30. http://dx.doi.org/10.1177/088532829100600202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kischkel, Sabine, Stefan Bergt, Beate Brock, Johan von Grönheim, Anne Herbst, Marc-Jonas Epping, Georg Matheis, et al. "In Vivo Testing of Extracorporeal Membrane Ventilators." ASAIO Journal 63, no. 2 (2017): 185–92. http://dx.doi.org/10.1097/mat.0000000000000465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "In-vivo testing"

1

William, V. G., Володимир Миколайович Дейнека, Владимир Николаевич Дейнека, Volodymyr Mykolaiovych Deineka, R. Gwendolen, Максим Володимирович Погорєлов, Максим Владимирович Погорелов, and Maksym Volodymyrovych Pohorielov. "In-vivo testing of spongy titanium implant biocompatibility." Thesis, Сумський державний університет, 2013. http://essuir.sumdu.edu.ua/handle/123456789/31970.

Full text
Abstract:
The conducted experiment shows porous titanium implant biocompatibility and existence of conductive features. This results leads to further research concerning this materials possible usage in osteoplasty. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/31970
APA, Harvard, Vancouver, ISO, and other styles
2

Cantu, Mark. "Shortened in Vivo Bioconcentration Factor Testing in Cyprinus Carpio." Thesis, University of North Texas, 2013. https://digital.library.unt.edu/ark:/67531/metadc407781/.

Full text
Abstract:
Bioconcentration factor testing serves as the most valuable surrogate for the assessment of bioaccumulation. The assessment of potentially harmful chemicals is crucial to not only the health of aquatic environments, but to humans as well. Chemicals that possess the ability to persist in the environment or that have the potential to bioaccumulate, pose a greater risk to organisms that are exposed to these chemicals. The Organization for Economic Cooperation and Development Guideline 305 outlines specific protocols to run an accurate and reliable aquatic flow-through test. However, since its adoption in 1996, very few changes have been made to accommodate the endeavor to lowering the amount of test species to run one of these said tests. Running an aquatic flow-through test, according to 305, takes much time and money as well as numerous amounts of fish. Such burdens can be eliminated through simple modifications to the standard protocols. In this study, we propose an abbreviated study design for aquatic bioconcentration testing which effectively alleviates the burdens of running a flow-through test. Four chemicals were used individually to evaluate the usefulness of the proposed shortened design; 4-Nonyphenol, Chlorpyrifos, Musk Xylene, and DDT. The study consisted of exposing Cyprinus carpio for 7 days followed by 7 days of depuration, for a total of a 14-day study. Our results for each of the four compounds are consistent with literature values, thus, demonstrating that BCFk can be accurately predicted in an abbreviated in vivo test.
APA, Harvard, Vancouver, ISO, and other styles
3

GAZZOLA, LUCA. "Field Testing of Software Applications." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2019. http://hdl.handle.net/10281/241221.

Full text
Abstract:
Quando interagiscono con sistemi software, gli utenti potrebbero dover affrontare problemi come crash, fallimenti e instabilità del programma. Il software difettoso in esecuzione sul campo non è solo la conseguenza di tecniche di verifica inefficaci, ma è anche dovuto alla complessità e alla diversità delle interazioni tra un'applicazione e il suo ambiente. Molte di queste interazioni sono difficilmente previste al momento del test, e anche quando potrebbero essere previste, spesso ci sono così tanti casi da testare che non possono essere affrontati in modo fattibile prima che il software sia rilasciato. Il testing sul campo si propone di affrontare il problema dei fallimenti delle applicazioni sul campo spostando la fase di test direttamente nell'ambiente di produzione. Ciò rende possibile sfruttare diversi scenari che altrimenti sarebbero difficili da catturare con test tradizionali. In questa tesi esploriamo l'area del testing sul campo del software, presentiamo uno studio che caratterizza il problema delle applicazioni che falliscono sul campo, un'architettura client-server che può essere sfruttata per organizzare e controllare il processo di test sul campo e un approccio di test che sfrutta l’ambiente di produzione come banco di prova per l'esecuzione dei test case. L'approccio presentato viene valutato empiricamente su un dataset di errori del software, dimostrando che il 35% dei guasti non rilevati internamente potrebbe essere stato rivelato con test sul campo.
When interacting with their software systems, users may have to deal with problems like crashes, failures, and program instability. Faulty software running in the field is not only the consequence of ineffective in-house verification and validation techniques, but it is also due to the complexity and diversity of the interactions between an application and its environment. Many of these interactions can be hardly predicted at testing time, and even when they could be predicted, often there are so many cases to be tested that they cannot be all feasibly addressed before the software is released. Field testing aims to tackle the problem of applications failing in the field by moving the testing phase directly in the field environment. This makes it possible to exploit different scenarios that would otherwise be difficult to capture with in-house testing. In this Ph.D. thesis we explore the area of software field testing, we present a study that characterizes the problem of applications failing in the field, a client-server architecture that can be exploited to organize and control the field testing process and a testing approach that exploits the field itself as testbed for running the test cases. The presented approach is empirically evaluated on a popular dataset of software faults demonstrating that 35% of the faults that were not discovered in-house could have been revealed with field testing.
APA, Harvard, Vancouver, ISO, and other styles
4

Charenkavanich, Panasaya. "Calibration of sonographic gel probe covers for in-vivo mechanical testing." Thesis, Massachusetts Institute of Technology, 2005. http://hdl.handle.net/1721.1/32870.

Full text
Abstract:
Thesis (S.B.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2005.
Includes bibliographical references (leaf 29).
Cervical insufficiency is a condition in pregnancy in which the cervix asymptomatically dilates in the absence of uterine contractions, resulting in a spontaneous preterm delivery. The condition is often misdiagnosed and presents a significant challenge for the clinical community. In order to establish better diagnostic criteria for cervical insufficiency and to improve assessment of preterm delivery risk for the individual patient, a non-invasive medical imaging tool, which uses ultrasound elastography to test the mechanical properties of cervical tissue, has been developed. The hand-held ultrasound indentation system will enable in vivo collection of stress-strain data from patients that will provide researchers with the necessary information to be used in material modeling and improve diagnosis of cervical insufficiency. The device consists of an ultrasound probe, enclosed by a gel-filled cover. The mechanical properties of the covers vary with each cap as well as with time and temperature. Therefore, in order to ensure accurate measurement, the probe covers must be calibrated prior to use. An experimental study was carried out to examine the effects of various testing conditions on the mechanical behavior of the probe covers. Different freezing and thawing techniques were explored in order to determine favorable conditions in order to preserve the integrity of the probes between the time of manufacture and actual use. From the results of the research, the appropriate combination of testing conditions for probe calibration was determined, as well as freezing and thawing techniques for probe preservation.
by Panasaya Charenkavanich.
S.B.
APA, Harvard, Vancouver, ISO, and other styles
5

Caminal, Bobet Marta. "Tissue engineering for bone regeneration: in vitro development and in vivo testing in sheep." Doctoral thesis, Universitat Autònoma de Barcelona, 2014. http://hdl.handle.net/10803/285622.

Full text
Abstract:
L'os és un teixit connectiu altament organitzat i especialitzat, la funció principal és la mecànica, proporcionant l'afecció als músculs i per tant permetent que el cos es mogui. Actualment, el tractament quirúrgic estàndard es basa en la immobilització i la introducció d'empelts ossis però presenta algunes complicacions, com ara les infeccions, les no unions i la morbiditat de la zona donant. Avui en dia, milions de pacients pateixen defectes ossis i en concret, als EEUU es diagnostiquen entre 10.000 i 20.000 nous casos d'osteonecrosi del cap de fèmur (ONFH) a l’any. La medicina regenerativa (RM) i l'enginyeria tissular (TE) són dos camps de la ciència que es centren en el desenvolupament de teràpies per reemplaçar i regenerar els teixits perduts o danyats per millorar la qualitat de vida del pacient. La combinació de biomaterials, cèl·lules i senyals és l’eina clau per al desenvolupament d'un producte RM i TE. Un dels camps més desenvolupats en RM és la medicina regenerativa ortopèdica, en concret per al teixit ossi. Hi ha diferents estratègies que combinen cèl·lules autòlogues amb matrius que han demostrat certa eficàcia en el tractament de lesions òssies. Després de la fase de descobriment de nous medicaments de teràpia avançada, i per tal d’aconseguir el registre del nou producte, hi ha la fase de desenvolupament, que inclou la realització d'estudis preclínics (fet per dur a terme la prova de concepte, la seguretat i toxicologia) i els estudis clínics. En primer lloc es van determinar i caracteritzar els components de la preparació d’enginyeria tissular (TEP) amb la finalitat d’obtenir un producte estandarditzat. Aquesta preparació consisteix en un component cel·lular que són les cèl·lules mesenquimals estromals (MSC), tant humanes com ovines unides en una matriu de partícules òssies desantigeneïtzades i liofilitzades. Es va realizar un model de defecte ossi de mida crítica (CSBD) en ovella amb la finalitat d'investigar l'efecte de la TEP en una situació extrema, i es va demostrar la seva seguretat i capacitat per sintetitzar nou os i remodelar l’os existent. Seguidament la TEP es va provar en un model animal rellevant de translació de la malaltia òssia basat en el mètode reportat per Vélez i col·laboradors per a la modelització de ONFH en ovelles demostrant la seva eficàcia i seguretat. També s’ha demostrat que les MSC estan involucrades en la síntesi d'os nou ja que es van trobar progenitors ossis marcats després del tractament de la ONFH, tot i així no es poden descartar els mecanismes paracrins. Per tant, el desenvolupament de la TEP podria contribuir en general a la RM per tal de satisfer les exigències d'una societat que envelleix.
Bone is a highly organized and specialized connective tissue, whose main function is the mechanics, providing attachment to muscles and therefore allowing the body to move. Currently the gold standard surgical treatment is based on the immobilization and introduction of bone grafts but it presents some complications, such as infections, non-unions, and donor site morbidity. Nowadays, millions of patients are suffering from bone defects and specifically, 10,000 to 20,000 new cases of osteonecrosis of femoral head (ONFH) are diagnosed only in the USA every year. Regenerative medicine (RM) and tissue engineering (TE) are two areas of science fields focused on the developing of therapies to replace and regenerate lost or damaged tissues to improve the quality of life the patient. The combination of biomaterials, cells and signals is the key tool for the development of a RM and TE product. One of the most developed fields in RM is the orthopedic regenerative medicine, in specifically for bone tissue. There are different strategies combining autologous cells with scaffolds that have shown some efficacy for treating bone injuries. After discovery phase of any new advanced therapy medicinal products, there is the development phase that includes the conduction of preclinical studies (made to perform the proof of concept, safety and toxicology) and clinical studies before the registration of the new product. First the components of the tissue engineered preparation (TEP) were determined and characterized in order to have a standardized material. It consists in MSC (mesenchymal stromal cells) both human and ovine sources are used as a cellular component seeded in a deantigenized and lyophilized bone particles as a scaffold. Then critical size bone defect (CSBD) was modeled in sheep in order to investigate the effect of the TEP in an extreme situation, demonstrating its safe ability to synthesize new bone and bone remodeling. Afterwards TEP was tested in a relevant translational animal model of bone disease based on the method reported by Velez and collaborators for modelling ONFH in sheep demonstrating its efficacy and safety. Also demonstrating that MSC were involved in the synthesis of new bone, because labeled bone progenitors are shown after ONFH treatment, although paracrine mechanisms can not be discarded. Therefore, the development of TEP could contribute to the overall RM to meet the requirements of an aging society.
APA, Harvard, Vancouver, ISO, and other styles
6

Kandala, Bala Subramanya Pavan Kumar. "Design, Fabrication, and Testing of Photo-chemically Etched Biodegradable Stents." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1593171197849115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Deblock, Michael C. "The Synthesis, In Vitro and In Vivo Testing of Silver N-Heterocyclic Carbenes and Imidazolium Complexes." University of Akron / OhioLINK, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=akron1353951003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Giesige, Carlee Rae. "Mouse model characterization and in vivo testing of gene therapies for Facioscapulohumeral Muscular Dystrophy." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu153193150617187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yamada, Tomoyuki. "In-vivo testing of a magnetically suspended centrifugal pump designed for long-term use." Kyoto University, 1999. http://hdl.handle.net/2433/181755.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tan, J. J. "Cardiosphere-derived stem cell culture, characterisation and labelling for in vivo testing in the infarcted heart." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:d902b4f4-6e32-45dd-9767-8e0a17967393.

Full text
Abstract:
Cardiac stem cells (CSCs), isolated from heart tissue explants and expanded via the formation of cardiospheres (Csp), are a promising candidate for cell therapy to prevent heart failure following myocardial infarction. To allow early administration to patients, isolation and expansion of CSCs must be performed in the shortest time possible. Hence, this project aimed to optimize culture conditions and characterize the cardiac explant-derived cells (EDCs), Csp and Csp-derived cells (CDCs) produced. Rat neonatal EDCs contained 4-7% c-kit+ cells, measured using flow cytometry. Optimal Csp growth conditions were determined, such that plating 3 x 10^4 EDCs per well of a 24-well plate coated with 16.7 µg/ml poly-D-lysine, in CGM containing 7% serum, improved Csp production and generated 1.5 x 10^7 CDCs in 16 days, a sufficient number for cell therapy. The CDCs expressed the stemness markers; c-kit, Oct3/4, SOX2, and Klf-4, and the cardiac differentiation markers; GATA4 and Nkx2.5. The therapeutic effect of CDCs may be limited by the low, 3 ± 0.1%, c-kit+ cell numbers. To increase c-kit+ cells in CDCs, an alternate culture method for Csp and different extracellular matrices (ECM) for cell expansion were tested. The hanging drop culture method produced Csp with higher levels of c-kit+ cells (9 ± 2%) than poly-D-lysine-coated and low-bind culture dishes. Of five ECM tested, collagen IV was found to enhance EDC migration and CDC proliferation, and produced 11 ± 0.4% c-kit+ cells, with Csp cultured in hanging drops. Intramyocardial injection of CDCs improved left ventricular ejection fractions of infarcted rat hearts by 9% and prevented the peri-infarct wall from thinning, measured in vivo using MRI over 16 weeks. To improve cell tracking using MRI, two MR positive contrast agents, gadolinium-DTPA and gadonanotubes were tested. Gd-DTPA had low sensitivity after labelling (1.4 x 10^5 cells/mm2); whereas gadonanotubes did not provide positive contrast at 11.7 T. Thus, neither contrast agent could be used for cell tracking using high magnetic field. In conclusion, CDCs were an effective source of stem cells that could be used for heart repair, although cells could not be tracked using positive MR contrast.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "In-vivo testing"

1

L, Arnold Douglas, Grice H. C, and Krewski D, eds. Handbook of in vivo toxicity testing. San Diego: Academic Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Clarke, Hilary. In vivo and in vitro studies on cyclosporine-induced nephrotoxicity. Dublin: University College Dublin, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

National Research Council (U.S.). Committee on Methods for the In Vivo Toxicity Testing of Complex Mixtures., ed. Complex mixtures: Methods for in vivo toxicity testing. Washington, D.C: National Academy Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1952-, Young David, Devane John G, and Butler Jackie, eds. In vitro-in vivo correlations. New York: Plenum Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

United States. Environmental Response Team, ed. Compendium of ERT toxicity testing procedures: Interim final. Washington, DC: Environmental Response Team, Emergency Response Division, Office of Emergency and Remedial Response, U.S. Environmental Protection Agency, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

C, Sahu Saura, and Casciano Daniel, eds. Nanotoxicity: In vivo and in vitro models to health risks. Chichester, West Sussex: John Wiley & Sons, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fano, Alix. Lethal laws: Animal testing, human health, and environmental policy. London: Zed Books, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1919-, Iwata Kazuo, and Bossche H. van den, eds. In Vitro and in vivo evaluation of antifungal agents: Proceedings of the International Symposium on In Vitro and In Vivo Evaluation of Antifungal Agents, held in Tokyo (Japan) on 19-22 June 1985. Amsterdam: Elsevier Science Publishers, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

C, Sahu Saura, and Casciano Daniel, eds. Nanotoxicity: From in vivo and in vitro models to health risks. Chichester, West Sussex, UK: John Wiley, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Williams, J. Andrew. Predictive approaches in drug discovery and development: Biomarkers and in vitro/in vivo correlations. Hoboken, N.J: Wiley, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "In-vivo testing"

1

Weber, Richard W. "In vivo testing." In Allergens and Allergen Immunotherapy, 85–93. Sixth edition. | Boca Raton : CRC Press/Taylor and Francis Group, [2020]: CRC Press, 2020. http://dx.doi.org/10.1201/9781351208994-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

González-Martín, Carmen, Esther Gramage, María José Polanco, and Carmen Rodríguez-Rivera. "In Vivo Toxicity Testing." In Toxicology for the Health and Pharmaceutical Sciences, 142–55. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9780203730584-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lijinsky, W. "In Vivo Testing for Carcinogenicity." In Handbook of Experimental Pharmacology, 179–209. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74775-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Simpson, Carrie A., Brian J. Huffman, and David E. Cliffel. "In Vivo Testing for Gold Nanoparticle Toxicity." In Methods in Molecular Biology, 175–86. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-468-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Abecassis, Pierre-Yves, and Céline Amara. "In Vivo Testing of Drug-Linker Stability." In Methods in Molecular Biology, 101–16. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-541-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pellacani, Giovanni, Stefania Guida, and Silvana Ciardo. "Novel Methods for In Vivo Skin Structure Visualization." In Practical Aspects of Cosmetic Testing, 265–88. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-44967-4_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hirano, Seishiro. "Chapter 3. In Vivo Testing of Nanomaterials." In Towards Efficient Designing of Safe Nanomaterials, 43–53. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849735476-00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gabard, B., and P. Treffel. "Correlation of in vitro and in vivo Testing." In Current Problems in Dermatology, 217–22. Basel: KARGER, 1998. http://dx.doi.org/10.1159/000060565.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mousa, Shaker A. "In Vivo or Ex Vivo Models for Testing Thrombosis and Hemostasis." In Drug Discovery and Evaluation: Pharmacological Assays, 1–43. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27728-3_13-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Corbett, Thomas, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh, Kathryn White, et al. "In Vivo Methods for Screening and Preclinical Testing." In Anticancer Drug Development Guide, 99–123. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-739-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "In-vivo testing"

1

Chu, Matt, Christian Murphy, and Gail Kaiser. "Distributed In Vivo Testing of Software Applications." In 2008 International Conference on Software Testing, Verification, and Validation. IEEE, 2008. http://dx.doi.org/10.1109/icst.2008.13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ceccato, Mariano, Luca Gazzola, Fitsum Meshesha Kifetew, Leonardo Mariani, Matteo Orru, and Paolo Tonella. "Toward In-Vivo Testing of Mobile Applications." In 2019 IEEE International Symposium on Software Reliability Engineering Workshops (ISSREW). IEEE, 2019. http://dx.doi.org/10.1109/issrew.2019.00063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lai, Wen-Yang, Kun-Che Tsai, Che Chen, and Yu-Sung Wu. "In-Vivo Fuzz Testing for Network Services." In 2022 41st International Symposium on Reliable Distributed Systems (SRDS). IEEE, 2022. http://dx.doi.org/10.1109/srds55811.2022.00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nishidate, Izumi, Satoko Kawauchi, Shunichi Sato, Manabu Sato, Yoshihisa Aizu, and Yasuaki Kokubo. "RGB camera-based functional imaging of in vivo biological tissues." In Optical Design and Testing VIII, edited by Yongtian Wang, Kimio Tatsuno, and Tina E. Kidger. SPIE, 2018. http://dx.doi.org/10.1117/12.2513306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ferche, Oana-Maria, Alin Dragos Bogdan Moldoveanu, Maria-Iuliana Dascalu, Constanta Nicoleta Bodea, Robert Gabriel Lupu, Danut Irimia, and Florica Moldoveanu. "The TRAVEE neuromotor rehabilitation system: In-vivo testing." In 2017 Zooming Innovation in Consumer Electronics International Conference (ZINC). IEEE, 2017. http://dx.doi.org/10.1109/zinc.2017.7968655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rosenberg, G., A. J. Snyder, W. J. Weiss, T. J. Cleary, and W. S. Pierce. "A permanent left ventricular-assist device: in vivo testing." In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1988. http://dx.doi.org/10.1109/iembs.1988.94408.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ceccato, Mariano, Davide Corradini, Luca Gazzola, Fitsum Meshesha Kifetew, Leonardo Mariani, Matteo Orru, and Paolo Tonella. "A Framework for In-Vivo Testing of Mobile Applications." In 2020 IEEE 13th International Conference on Software Testing, Validation and Verification (ICST). IEEE, 2020. http://dx.doi.org/10.1109/icst46399.2020.00037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yu, H., L. Ai, M. Rouhanizadeh, T. K. Hsiai, E. S. Kim, and R. A. Kloner. "FLEXIBLE SHEAR STRESS SENSOR FOR IN VIVO CARDIOVASCULAR TESTING." In 2008 Solid-State, Actuators, and Microsystems Workshop. San Diego: Transducer Research Foundation, 2008. http://dx.doi.org/10.31438/trf.hh2008.39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bertolino, Antonia, Guglielmo De Angelis, Breno Miranda, and Paolo Tonella. "Run Java Applications and Test Them In-Vivo Meantime." In 2020 IEEE 13th International Conference on Software Testing, Validation and Verification (ICST). IEEE, 2020. http://dx.doi.org/10.1109/icst46399.2020.00061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Murphy, Christian, Gail Kaiser, Ian Vo, and Matt Chu. "Quality Assurance of Software Applications Using the In Vivo Testing Approach." In 2009 International Conference on Software Testing Verification and Validation (ICST). IEEE, 2009. http://dx.doi.org/10.1109/icst.2009.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "In-vivo testing"

1

MacLellan, J. A., R. J. Traub, and P. C. Olsen. Performance testing of radiobioassay laboratories: In vivo measurements, Final Report. Office of Scientific and Technical Information (OSTI), April 1990. http://dx.doi.org/10.2172/6998364.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Robinson, A. V., D. R. Fisher, W. D. Reece, and J. A. MacLellan. Performance testing of radiobioassay laboratories: in-vivo measurements, pilot study report. Office of Scientific and Technical Information (OSTI), October 1986. http://dx.doi.org/10.2172/7154251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Waters, David J. In Vivo Testing of Chemopreventive Agents Using the Dog Model of Spontaneous Prostate Carcinogenesis. Fort Belvoir, VA: Defense Technical Information Center, March 2001. http://dx.doi.org/10.21236/ada398171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Waters, David J. In Vivo Testing of Chemopreventive Agents Using the Dog Model of Spontaneous Prostate Carcinogenesis. Fort Belvoir, VA: Defense Technical Information Center, March 2003. http://dx.doi.org/10.21236/ada418684.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

MacLellan, J. A., and R. J. Traub. Recommended procedures for performance testing of radiobioassay laboratories: Volume 3, In vivo test phantoms. Office of Scientific and Technical Information (OSTI), November 1988. http://dx.doi.org/10.2172/6878277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Spiers, Donald, Arieh Gertler, Harold Johnson, and James Spain. An In Vitro and In Vivo Investigation of the Diverse Biological Activities of Bovine Placental Lactogen. United States Department of Agriculture, August 1993. http://dx.doi.org/10.32747/1993.7568087.bard.

Full text
Abstract:
In order to understand the structure-function relationship of bovine placental lactogen (bPL) and initiate production of material for in vivo testing, 28 different bPL analogues were prepared by either truncation or site-directed mutagenesis. The effect of these mutations was determined by measuring binding capacity, ability to homodimerize extracellular domains (ECDs) of several lactogenic and somatogenic receptors, and by in vitro bioassays. Two analogues were prepared in large amounts for in vivo studies. These studies (a) identified the residues responsible for the somatogenic activity of bPL (K73, G133, T188) and for both lactogenic and somatogenic activity (N-terminus, K185, Y190); (b) allowed preparation of bPL analogues with selectively abolished or reduced somatogenic activity; and (c) provided a tool to understand the kinetic difference between lactogenic and somatogenic receptors. In vivo studies using rodent and dairy models showed that bovine growth hormone (bGH) is superior to bPL in stimulating growth and lactation. Likewise, bGH has greater somatogenic activity in different age groups and thermal environments. Initial studies of bPL analog T188 suggest that its lactogenic potential is superior to bGH. Effective experimental models have now been developed and tested for analysis of new bPL analogs.
APA, Harvard, Vancouver, ISO, and other styles
7

Shpigel, Nahum, Raul Barletta, Ilan Rosenshine, and Marcelo Chaffer. Identification and characterization of Mycobacterium paratuberculosis virulence genes expressed in vivo by negative selection. United States Department of Agriculture, January 2004. http://dx.doi.org/10.32747/2004.7696510.bard.

Full text
Abstract:
Mycobacterium avium subsp. paratuberculosis (MAP) is the etiological agent of a severe inflammatory bowel disease (IBD) in ruminants, known as Johne’s disease or paratuberculosis. Johne’s disease is considered to be one of the most serious diseases affecting dairy cattle both in Israel and worldwide. Heavy economic losses are incurred by dairy farmers due to the severe effect of subclinical infection on milk production, fertility, lower disease resistance and early culling. Its influence in the United States alone is staggering, causing an estimated loss of $1.5 billion to the agriculture industry every year. Isolation of MAP from intestinal tissue and blood of Crohn's patients has lead to concern that it plays a potential pathogenic role in promoting human IDB including Crohn’s disease. There is great concern following the identification of the organism in animal products and shedding of the organism to the environment by subclinically infected animals. Little is known about the molecular basis for MAP virulence. The goal of the original proposed research was to identify MAP genes that are required for the critical stage of initial infection and colonization of ruminants’ intestine by MAP. We proposed to develop and use signature tag mutagenesis (STM) screen to find MAP genes that are specifically required for survival in ruminants upon experimental infection. This research projected was approved as one-year feasibility study to prove the ability of the research team to establish the animal model for mutant screening and alternative in-vitro cell systems. In Israel, neonatal goat kids were repeatedly inoculated with either one of the following organisms; MAP K-10 strain and three transposon mutants of K-10 which were produced and screened by the US PI. Six months after the commencement of inoculation we have necropsied the goats and taken multiple tissue samples from the jejunum, ileum and mesenteric lymph nodes. Both PCR and histopathology analysis indicated on efficient MAP colonization of all the inoculated animals. We have established several systems in the Israeli PI’s laboratory; these include using IS900 PCR for the identification of MAP and using HSP65-based PCR for the differentiation between MAV and MAP. We used Southern blot analysis for the differentiation among transposon mutants of K-10. In addition the Israeli PI has set up a panel of in-vitro screening systems for MAP mutants. These include assays to test adhesion, phagocytosis and survival of MAP to/within macrophages, assays that determine the rate of MAPinduced apoptosis of macrophages and MAP-induced NO production by macrophages, and assays testing the interference with T cell ã Interferon production and T cell proliferation by MAP infected macrophages (macrophage studies were done in BoMac and RAW cell lines, mouse peritoneal macrophages and bovine peripheral blood monocytes derived macrophages, respectively). All partners involved in this project feel that we are currently on track with this novel, highly challenging and ambitious research project. We have managed to establish the above described research systems that will clearly enable us to achieve the original proposed scientific objectives. We have proven ourselves as excellent collaborative groups with very high levels of complementary expertise. The Israeli groups were very fortunate to work with the US group and in a very short time period to master numerous techniques in the field of Mycobacterium research. The Israeli group has proven its ability to run this complicated animal model. This research, if continued, may elucidate new and basic aspects related to the pathogenesis MAP. In addition the work may identify new targets for vaccine and drug development. Considering the possibility that MAP might be a cause of human Crohn’s disease, better understanding of virulence mechanisms of this organism might also be of public health interest as well.
APA, Harvard, Vancouver, ISO, and other styles
8

Olsen, P., and T. Lynch. A suitability study of the fission product phantom and the bottle manikin absorption phantom for calibration of in vivo bioassay equipment for the DOELAP accreditation testing program. Office of Scientific and Technical Information (OSTI), August 1991. http://dx.doi.org/10.2172/5364793.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Boisclair, Yves R., and Arieh Gertler. Development and Use of Leptin Receptor Antagonists to Increase Appetite and Adaptive Metabolism in Ruminants. United States Department of Agriculture, January 2012. http://dx.doi.org/10.32747/2012.7697120.bard.

Full text
Abstract:
Objectives The original project had 2 major objectives: (1) To determine the effects of centrally administered leptin antagonist on appetite and adaptive metabolism in the sheep; (2) To develop and prepare second-generation leptin antagonists combining high binding affinity and prolonged in vivo half-life. Background Periods of suboptimal nutrition or exaggerated metabolic activity demands lead to a state of chronic energy insufficiency. Ruminants remain productive for a surprisingly long period of time under these circumstances by evoking adaptations sparing available energy and nutrients. The mechanism driving these adaptations in ruminant remains unknown, but could involve a reduction in plasma leptin, a hormone acting predominantly in the brain. In laboratory animals, reduced leptin signaling promotes survival during nutritional insufficiency by triggering energy sparing adaptations such as reduced thyroid hormone production and insulin resistance. Our overall hypothesis is that similar adaptations are triggered by reduced leptin signaling in the brain of ruminants. Testing of this hypothesis in ruminants has not been possible due to inability to block the actions of endogenous leptin and access to ruminant models where leptin antagonistic therapy is feasible and effective. Major achievements and conclusions The Israeli team had previously mutated 3 residues in ovine leptin, with no effect on receptor binding. This mutant was renamed ovine leptin antagonist (OLA) because it cannot activate signaling and therefore antagonizes the ability of wild type leptin to activate its receptor. To transform OLA into an effective in vivo antagonist, the Israeli made 2 important technical advances. First, it incorporated an additional mutation into OLA, increasing its binding affinity and thus transforming it into a super ovine leptin antagonist (SOLA). Second, the Israeli team developed a method whereby polyethylene glycol is covalently attached to SOLA (PEG-SOLA) with the goal of extending its half-life in vivo. The US team used OLA and PEG-SOLA in 2 separate animal models. First, OLA was chronically administered directly into the brain of mature sheep via a cannula implanted into the 3rdcerebroventricule. Unexpectedly, OLA had no effect of voluntary feed intake or various indicators of peripheral insulin action but reduced the plasma concentration of thyroid hormones. Second, the US team tested the effect of peripheral PEG-SOLA administration in an energy sensitive, rapidly growing lamb model. PEG-SOLA was administered for 14 consecutive days after birth or for 5 consecutive days before sacrifice on day 40 of life. Plasma PEG-SOLA had a half-life of over 16 h and circulated in 225- to 288-fold excess over endogenous leptin. PEG-SOLA administration reduced plasma thyroid hormones and resulted in a higher fat content in the carcass at slaughter, but had no effects on feed intake, body weight, plasma glucose or insulin. These results show that the team succeeded in developing a leptin antagonist with a long in vivo half-life. Moreover, in vivo results show that reduced leptin signaling promotes energy sparing in ruminants by repressing thyroid hormone production. Scientific and agricultural implications The physiological role of leptin in ruminants has been difficult to resolve because peripheral administration of wild type leptin causes little effects. Our work with leptin antagonists show for the first time in ruminants that reduced leptin signaling induces energy sparing mechanisms involving thyroid hormone production with little effect on peripheral insulin action. Additional work is needed to develop even more potent leptin antagonists, to establish optimal administration protocols and to narrow down phases of the ruminant life cycle when their use will improve productivity.
APA, Harvard, Vancouver, ISO, and other styles
10

Cao, Siyang, Yihao Wei, Tiantian Qi, Peng Liu, Yingqi Chen, Fei Yu, Hui Zeng, and Jian Weng. Stem cell therapy for peripheral nerve injury: An up-to-date meta-analysis of 55 preclinical researches. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0083.

Full text
Abstract:
Review question / Objective: It has been the gold standard for decades to reconstruct a large peripheral nerve injury with a nerve autograft, and this remains true today as well. In addition to nerve autografts, biological conduits and vessels can also be applied. A fair amount of studies have examined the benefits of adding stem cells to the lumen of a nerve conduit. The aim of this meta-analysis was to summarize animal experiments related to the utilization of stem cells as a luminal additive when rebuilding a peripheral nerve injury using nerve grafts. Eligibility criteria: The inclusion criteria were as following: 1.Reconstruction of peripheral nerve injury; 2.Complete nerve transection with gap defect created; 3.Animal in-vivo models; 4.Experimental comparisons between nerve conduits containing and not containing one type of stem cell; 5.Functional testing and electrophysiology evaluations are performed. The exclusion criteria were as following: 1.Repair of central nervous system; 2.Nerve repair is accomplished by end-to-end anastomosis; 3.Animal models of entrapment injuries, frostbite, traction injuries and electric injuries; 4.Nerve conduits made from autologous epineurium; 5.Clinical trials, reviews, letters, conference papers, meta-analyses or commentaries; 6.Same studies have been published in different journals under the same or a different title.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'In-vivo testing' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography